Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06309355 · ClinicalTrials.gov registry record · Phase 2
Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Hangzhou Yirui Pharmaceutical Technology Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 4
- Study locations
NCT06309355: Completed Phase 2 study of Atopic Dermatitis, sponsored by Hangzhou Yirui Pharmaceutical Technology Co..
NCT06309355 is a Phase 2 study of Atopic Dermatitis that has completed, run by Hangzhou Yirui Pharmaceutical Technology Co.. The registered enrollment target is 35 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06309355, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Hangzhou Yirui Pharmaceutical Technology Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic dermatitis
Primary Outcome
incidence of treatment related AEs (TRAEs)
Conditions Studied
Interventions
- OTHER Placebo
- DRUG YR001 ointment
Study Locations (4)
Florida
- Encore Medical Research -Boynton Beach - Boynton Beach
- Encore Medical Research-Hollywood - Hollywood
- Encore Medical Research-Weston - Weston
Louisiana
- DelRicht Research - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2025-11-20 |
| Phase | Phase 2 |
What the finished NCT06309355 record still lists
NCT06309355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06309355 reports a single indexed study location in Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06309355 about?
NCT06309355 is a clinical study titled "Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis". This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic dermatitis
What is the current status of trial NCT06309355?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2024-06-19. Estimated completion is 2025-11-20.
What conditions does trial NCT06309355 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06309355?
The interventions under investigation include: Placebo (OTHER), YR001 ointment (DRUG).
Who is sponsoring clinical trial NCT06309355?
This trial is sponsored by Hangzhou Yirui Pharmaceutical Technology Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06309355 being conducted?
This trial has 4 study locations across Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06309355's enrollment target sits among peer trials
35 117th of 150 higher than 33 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI